Idexx Laboratories Inc /De IDXX

Revenue Intelligence Report • 69 quarters of SEC filing data • Updated 2026-10-14 • Data through 2026-06-30

Idexx Laboratories Inc /De's latest quarterly revenue is $1.2B for the period ending 2026-06-30. The model projects $4.8B across the next four quarters (+6.2% versus the preceding four quarters). The forecast uses SG&A data; model selection and estimation exclude the latest quarter, whose retrospective holdout error is 3.4%. These are statistical associations, not estimates of the causal effect of spending.

Investment Thesis

The ARDL forecast is based on reported revenue and SG&A data through 2026-06-30. Training MAPE measures fit to historical data; the separately reported holdout error measures a withheld quarter. Spending coefficients describe associations and do not establish causation.

Next 4 Quarters
$4.84B
+6.2% YoY
R&D Elasticity
-0.67x
SG&A Elasticity
0.04x
Training Fit
2.4% MAPE
Retrospective holdout (Q2 FY2026): The model predicted $1.17B vs the actual $1.22B — an error of 3.4%.
Retrospective one-quarter holdout: model fitting and selection exclude this quarter. Historical inputs use the latest available restatements, so this is not a preserved real-time forecast.
⚠ Model limitation: One or more estimated spending associations are negative. These observational coefficients do not establish a causal return on spending.

Revenue Forecast

IDXX Revenue Forecast

Quarterly Detail

QuarterModel ForecastActual95% RangeYoY GrowthStatus
Q2 FY2026
Period end 2026-06-30		 $1.17B $1.22B $1.10B–$1.25B +5.9% ✓ In range
Q3 FY2026
Period end 2026-09-30		 $1.19B $1.09B–$1.30B +7.3%
Q4 FY2026
Period end 2026-12-31		 $1.19B $1.07B–$1.32B +8.8%
Q1 FY2027
Period end 2027-03-31		 $1.23B $1.08B–$1.39B +7.4%
Q2 FY2027
Period end 2027-06-30		 $1.24B $1.08B–$1.42B +1.9%

Seasonal Factors

Multiplicative seasonal adjustment: These factors capture Idexx Laboratories Inc /De's systematic quarterly revenue patterns relative to the trend model. A factor of 1.05 means that quarter typically runs 5% above the underlying trend; 0.95 means 5% below. Factors are computed as the median of (actual / fitted) across all available quarters.
Fiscal QuarterSeasonal Factorvs TrendInterpretationObs.
FQ1 (Jan–Mar) 0.9977 -0.2% In line with trend 16
FQ2 (Apr–Jun) 1.0097 +1.0% In line with trend 16
FQ3 (Jul–Sep) 0.9773 -2.3% In line with trend 16
FQ4 (Oct–Dec) 0.9967 -0.3% In line with trend 16

Spending and Revenue

IDXX Spending Timing
Reading this chart: Each line shows the cumulative revenue association with a 1% change in spending over subsequent quarters. These estimates describe historical associations and do not establish causation.

Time-Varying Spending Associations

Time-varying analysis: A penalized spline model (GAM) tracks the association between log spending and log revenue over 69 quarters. Its coefficients describe conditional historical associations, not causal returns on spending.
Current SG&A elasticity: 0.2458x • R&D elasticity: -0.0372x
The model-term chart shows relative absolute term magnitudes. Its percentages are not shares of revenue or causal contributions to growth.

Want this analysis for your portfolio?

I build custom revenue intelligence reports for investors and companies using SEC filing data, econometric modeling, and AI-powered insights.

Get in Touch

Data sourced from SEC EDGAR XBRL filings. SEC source data. Forecast model: ARDL; spending associations: ARDL (log-log) with 69 quarters. This analysis is for informational purposes only and does not constitute investment advice.

More in Healthcare

ABT BMY A CAH COO INCY PFE WST